Last Updated: November 16, 2026

Details for Patent: 11,701,330

« Back to Dashboard


Summary for Patent: 11,701,330
Title:Use of cannabinoids in the treatment of epilepsy
Abstract:The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s):Geoffrey Guy, Stephen Wright, Orrin Devinsky
Assignee: GW Pharma Ltd , Jazz Pharmaceuticals Research UK Ltd
Application Number:US17/472,016
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,701,330
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Executive summary: U.S. Patent No. 11,701,330 protects a narrow treatment protocol for cannabidiol in Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS). The independent claim requires all of the following: a qualifying treatment-resistant epilepsy, a CBD drug substance containing at least 98% CBD, administration beginning at approximately 5 mg/kg/day, dose escalation in approximately 5 mg/kg increments, and liver-function testing. Dependent claims add maximum doses, 10 mg/kg/day and 20 mg/kg/day regimens, synthetic CBD, impurity specifications, seizure-reduction outcomes, and testing at baseline, four weeks, or 12 weeks.

The patent does not claim CBD as a chemical compound, a CBD formulation in the abstract, or every use of Epidiolex. Its commercial relevance is concentrated on a labeled or substantially equivalent dosing-and-monitoring protocol for Epidiolex or another highly purified CBD product used in LGS or DS.

U.S. Patent 11,701,330 CBD Epilepsy Patent Scope, Claims, Expiration, and Competitive Landscape

What does U.S. Patent 11,701,330 protect?

The patent protects methods of treating seizures associated with LGS or DS using a highly purified CBD drug substance while monitoring liver function and escalating the dose from approximately 5 mg/kg/day.

Claim 1 is the controlling independent claim. A practicing party must satisfy each limitation:

Required limitation in claim 1 Scope
Patient A patient in need of treatment
Disease Treatment-resistant epilepsy that is LGS or DS
Therapeutic objective Treatment of seizures
Product Pharmaceutical composition containing a CBD drug substance
CBD purity At least 98% w/w CBD
Monitoring Testing liver function
Starting dose Approximately 5 mg/kg/day
Escalation Increase by approximately 5 mg/kg increments

The claim is cumulative. A method that meets the disease, product, and dose requirements but does not include liver-function testing would not literally satisfy claim 1. Conversely, liver testing alone does not create infringement unless the remaining disease, purity, and dosing limitations are also met.

The patent is therefore a regimen patent with product-quality limitations. It is not a broad composition-of-matter patent.

How do the dependent claims expand the patent’s scope?

Claims 2 through 30 divide into five principal groups: dose limits, product purity, clinical outcomes, disease-specific regimens, and liver-function testing schedules.

Dose-escalation claims

Claims 2 through 5 cover dose escalation to:

  • A maximum of approximately 25 mg/kg/day;
  • Approximately 10 mg/kg/day;
  • Approximately 20 mg/kg/day; or
  • A range of approximately 10 mg/kg/day to approximately 20 mg/kg/day.

Claims 18 through 25 apply the 10 mg/kg/day and 20 mg/kg/day regimens specifically to LGS and DS.

The “about” language gives the claims some numerical flexibility, but it does not eliminate the need to prove that the accused regimen falls within the claim’s dose range. A fixed-dose product administered outside the claimed titration sequence presents a stronger non-infringement position than a product administered at the same endpoint dose through a materially different protocol.

Synthetic CBD

Claim 6 requires synthetic CBD. It narrows the claim rather than expanding it. A botanical CBD product may fall within claim 1 if it satisfies the other limitations, but it would not satisfy claim 6 solely because it contains at least 98% CBD.

The synthetic-CBD limitation may have practical importance for suppliers using chemically synthesized cannabidiol rather than plant-derived cannabidiol. It also separates the patent from claims directed only to botanical extracts or full-spectrum cannabis preparations.

Impurity specifications

Claims 7 and 8 impose limits on specified cannabinoids and related compounds:

Component Maximum concentration
Δ9-THC Not more than 0.15% w/w
CBDA Not more than 0.15% w/w
CBDV Not more than 1.0% w/w
CBD-C4 Not more than 0.5% w/w

These claims create a product-testing issue in addition to a treatment-method issue. A potential challenger would need analytical data for the CBD drug substance used in the accused product. Batch-specific certificates of analysis, validated assay methods, and manufacturing specifications would be relevant to both infringement and invalidity disputes.

Seizure-reduction outcomes

Claims 9 through 17 and claims 19 and 23 address treatment of convulsive seizures, reduction in seizure frequency, and at least a 50% reduction in convulsive seizure frequency compared with a baseline period.

The baseline comparison is important. Claims requiring a 50% reduction contain an outcome limitation. In a litigation setting, evidence could include seizure diaries, caregiver reports, clinical records, trial data, or treatment-protocol documents. Claims 9, 10, 12, 13, 15, and 16 do not expressly require a 50% reduction, but claims 11, 14, and 17 do.

Liver-function testing

Claims 26 through 30 cover testing:

  • At baseline;
  • After CBD administration;
  • Four weeks after treatment begins;
  • Twelve weeks after treatment begins; or
  • At baseline and after treatment.

These claims make monitoring conduct a central part of the patent estate. The required testing is not limited in the supplied claims to a specific laboratory analyte, such as alanine aminotransferase or aspartate aminotransferase. The specification and prosecution history would determine how broadly “testing liver function” is construed.

How does the patent compare with the FDA-approved Epidiolex regimen?

The claimed regimen closely tracks the FDA-approved use of cannabidiol oral solution for seizures associated with LGS or DS.

The Epidiolex prescribing information describes a starting dosage of 2.5 mg/kg twice daily, equivalent to 5 mg/kg/day. After one week, the dosage can be increased to 5 mg/kg twice daily, equivalent to 10 mg/kg/day. For LGS and DS, the maximum recommended dosage is generally 10 mg/kg twice daily, equivalent to 20 mg/kg/day. The label also requires liver-function evaluation before treatment and monitoring during treatment, particularly in the presence of valproate or clobazam (U.S. Food and Drug Administration, 2024).

Feature Patent claims Epidiolex labeling
Indications LGS or DS LGS or DS
Starting daily dose About 5 mg/kg/day 5 mg/kg/day
Escalation About 5 mg/kg increments Increase to 10 mg/kg/day after one week
Common maximum Claims include 20 mg/kg/day and up to 25 mg/kg/day 20 mg/kg/day
Liver monitoring Required by claim 1 Required by labeling
CBD purity At least 98% w/w CBD Product-specific CMC specification
Drug source Claims include synthetic CBD in claim 6 Epidiolex contains highly purified CBD

The overlap is commercially significant. A labeled administration of Epidiolex for LGS or DS can align with the disease, dose, and monitoring limitations of the patent. That alignment does not by itself establish infringement because the product’s actual CBD specification, the prescribing conduct, the dose-escalation sequence, and the relevant patent term must also be established.

What is the patent’s claim strategy?

The patent uses a layered claim structure.

Broadest practical layer

Claim 1 combines the disease, CBD purity, liver testing, starting dose, and dose escalation. It is the principal enforcement claim.

Dose-specific layer

Claims 2 through 5 and 18 through 25 preserve protection around the 10 mg/kg/day and 20 mg/kg/day regimens. These claims are commercially important because they correspond to the principal clinical dosing levels for Epidiolex.

Product-quality layer

Claims 6 through 8 target synthetic CBD and specified impurity profiles. These claims may be harder to assess without access to manufacturing and batch records.

Clinical-result layer

Claims 9 through 17, 19, and 23 add seizure reduction and, in some cases, a 50% reduction from baseline. These claims may have narrower practical coverage because they require proof of patient outcomes.

Monitoring layer

Claims 26 through 30 cover liver testing at specific treatment stages. These claims may be relevant to a product label, clinical protocol, pharmacy service, or prescriber instruction that incorporates the monitoring schedule.

What patents protect Epidiolex and purified CBD beyond U.S. Patent 11,701,330?

Epidiolex protection has historically involved several patent categories:

Patent category Typical protected subject matter Relevance to 11,701,330
Therapeutic-use patents CBD treatment for LGS, DS, and seizure reduction Directly overlapping category
Dosing patents Starting dose, titration, maximum dose, and patient populations Directly overlapping category
Formulation patents Oral solutions, excipients, concentration, and delivery characteristics Potentially separate
Manufacturing patents Purification, synthetic preparation, impurity control, and scale-up Related to claims 6-8
Regulatory exclusivity FDA orphan-drug and approval exclusivity Independent of patent term
Trademark and trade-secret rights Epidiolex branding and manufacturing know-how Not patent protection

U.S. Patent 11,701,330 should therefore be analyzed as one component of the Epidiolex estate, not as the complete CBD patent position. A freedom-to-operate review would need to examine the patent family, continuation applications, terminal disclaimers, Orange Book entries, and any separately issued formulation or manufacturing patents.

What is the Orange Book status of U.S. Patent 11,701,330?

The supplied claim text establishes that the patent contains method-of-use claims, but it does not establish an Orange Book listing, listing date, use code, pediatric exclusivity, patent-term adjustment, or patent-term extension.

For an NDA product such as Epidiolex, a method-of-use patent may be submitted for Orange Book listing if it claims an approved method of using the drug. The commercial effect of listing depends on:

  1. Whether the patent was submitted and accepted for listing;
  2. Whether the listed use code corresponds to LGS, DS, dose escalation, or monitoring;
  3. Whether a generic applicant must certify to the patent;
  4. Whether a Paragraph IV notice was served;
  5. Whether the NDA holder filed suit within the statutory period; and
  6. Whether the patent remains unexpired when the ANDA is otherwise eligible for approval.

An Orange Book listing does not establish patent validity. It creates a regulatory certification and litigation framework under the Hatch-Waxman Act.

When does U.S. Patent 11,701,330 lose exclusivity?

The expiration date cannot be derived reliably from the issue date alone. U.S. utility patents generally expire 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable priority claims (U.S. Patent and Trademark Office, 2024).

For this patent, the decisive term variables are:

  • The earliest effective priority date;
  • The application chain leading to Patent No. 11,701,330;
  • Any continuation or divisional relationship;
  • Patent-term adjustment shown on the issued patent record;
  • Any terminal disclaimer;
  • Any Hatch-Waxman patent-term extension; and
  • Pediatric exclusivity associated with the approved product.

The 20-year patent term is distinct from FDA regulatory exclusivity. Epidiolex received orphan-drug exclusivity for the approved LGS and DS indications. Orphan exclusivity generally protects the approved indication for seven years from approval, while patent protection can continue beyond that period. The two forms of exclusivity should not be treated as interchangeable.

What Paragraph IV challenges and generic entry risks apply?

A generic applicant seeking approval for cannabidiol oral solution could use one of four principal certification positions:

Certification Effect
Paragraph I No patent information has been submitted
Paragraph II Listed patents have expired
Paragraph III The applicant will wait until patent expiration
Paragraph IV The listed patent is invalid, unenforceable, or not infringed

For this patent, a Paragraph IV strategy could target one or more limitations:

  • The generic is not labeled for LGS or DS;
  • The proposed label omits the claimed titration protocol;
  • The product does not meet the claimed CBD purity or impurity limits;
  • The proposed use does not require liver-function testing;
  • The product uses a non-synthetic CBD source;
  • The claimed dose range is not included in the proposed labeling; or
  • The claims are invalid for anticipation, obviousness, lack of written description, enablement, or indefiniteness.

The strongest practical non-infringement position would generally involve a proposed label that omits the patented indication or dosing instructions. That strategy is constrained if the generic seeks approval for the same LGS or DS uses and adopts the same labeled titration and monitoring protocol.

How strong is the patent estate?

The patent has meaningful commercial relevance but a narrower legal perimeter than a composition-of-matter patent.

Strength factor Assessment
Alignment with FDA labeling Strong
Coverage of LGS and DS Strong
Coverage of 5-to-10-to-20 mg/kg/day titration Strong
Dependence on liver-function testing Creates a material proof requirement
Dependence on CBD purity Requires product- and batch-specific evidence
Coverage of all CBD products Limited
Protection against non-CBD antiseizure products None
Protection against off-label or alternative dosing Variable
Vulnerability to label carve-outs Material
Manufacturing barrier Moderate for claimed impurity profiles, unless supported by separate process patents

The patent is more valuable against a generic that copies the Epidiolex indication, dose escalation, and monitoring instructions than against a product with a materially different label or clinical protocol.

What litigation and settlement issues should be reviewed?

The relevant litigation questions are:

  1. Whether Patent No. 11,701,330 was included in a patent-infringement complaint against an ANDA applicant;
  2. Whether the patent was asserted together with earlier GW Pharmaceuticals or Jazz Pharmaceuticals CBD patents;
  3. Whether defendants raised invalidity or non-infringement defenses;
  4. Whether any settlement included a delayed generic-entry date;
  5. Whether the settlement included a license, authorized-generic arrangement, or supply agreement; and
  6. Whether the patent was later cancelled, amended, or confirmed in post-grant proceedings.

A patent-by-patent review of PACER, the Orange Book, USPTO Patent Center, and FDA listing data is required to attribute a specific Paragraph IV case or settlement to Patent No. 11,701,330. The supplied claims alone do not identify a litigant, case number, settlement date, or entry date.

What are the principal commercial scenarios for generic entry?

Same-label entry

A generic copies the LGS and DS indications and the 5 mg/kg/day starting regimen. This presents the highest direct infringement exposure under claim 1.

Carved-out indication

A generic omits LGS, DS, or the patented seizure use from its label. This can reduce method-of-use exposure but may limit the approved market.

Alternative dosing protocol

A generic uses a different titration schedule or omits the claimed escalation sequence. This may avoid literal infringement but could create regulatory and clinical limitations.

Different CBD source

A generic uses botanical rather than synthetic CBD. This may avoid claim 6 but does not avoid claim 1 if the product still meets the other limitations.

Different impurity profile

A product outside the claimed impurity thresholds may avoid claims 7 and 8. It would still require analysis under claim 1’s 98% CBD requirement.

Key Takeaways

  • U.S. Patent 11,701,330 is a method-of-treatment patent centered on purified CBD dosing and liver-function monitoring.
  • Claim 1 requires LGS or DS, at least 98% CBD, a starting dose of about 5 mg/kg/day, 5 mg/kg dose increments, and liver testing.
  • Claims 2 through 30 create narrower protection around 10 mg/kg/day, 20 mg/kg/day, 25 mg/kg/day, synthetic CBD, impurity limits, seizure reduction, and monitoring at baseline, four weeks, or 12 weeks.
  • The claims closely track the FDA-approved Epidiolex regimen.
  • The patent does not independently claim CBD as a molecule or every CBD formulation.
  • Generic risk is highest when a proposed label copies the Epidiolex LGS or DS indications, titration schedule, and liver-monitoring instructions.
  • Exact expiration, Orange Book listing, Paragraph IV activity, litigation, and settlements require review of the patent record, FDA Orange Book data, and court filings.

FAQs

Does Patent 11,701,330 cover all cannabidiol products?

No. The supplied claims require a treatment method involving LGS or DS, a CBD drug substance containing at least 98% CBD, dose escalation, and liver-function testing.

Does synthetic CBD automatically infringe the patent?

No. Synthetic CBD is expressly required only by dependent claim 6. A product must also satisfy the limitations inherited from claim 1.

Is a 20 mg/kg/day Epidiolex regimen within the patent claims?

It can be. Claims 4, 18 through 21, and 22 through 25 expressly address approximately 20 mg/kg/day, subject to the remaining claim limitations.

Can a generic avoid the patent by using a different CBD formulation?

Not necessarily. A different formulation may avoid a separate formulation patent, but it could still fall within the method claims if it meets the disease, purity, dosing, escalation, and monitoring requirements.

Does FDA approval prove infringement of Patent 11,701,330?

No. FDA labeling may overlap with the patent, but infringement requires proof that every limitation of an asserted claim is met, either literally or under the doctrine of equivalents.

References

  1. U.S. Food and Drug Administration. (2024). Epidiolex (cannabidiol) oral solution prescribing information. FDA.

  2. U.S. Patent and Trademark Office. (2023). U.S. Patent No. 11,701,330. USPTO Patent Center.

  3. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation. U.S. Department of Commerce.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  5. U.S. Food and Drug Administration. (2018). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. FDA.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,701,330

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Jazz Pharms Res EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME ⤷  Start Trial
Jazz Pharms Res EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.